VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reached a key development milestone in its oncology pipeline. The company announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development. This progress follows the successful completion of the discovery portion of VERAXA's collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz).
With the discovery work completed, VERAXA will now focus on engineering the final bispecific ADC candidate by combining the antibody binders identified through the OmniAb collaboration with its proprietary antibody engineering, linker, and conjugation technologies. Although VXA-222 is not based on VERAXA's BiTAC platform, it leverages these core technologies and represents one of the company's more advanced development programs. The milestone reflects continued progress across VERAXA's therapeutic portfolio as it simultaneously expands its intellectual property supporting next-generation antibody-based cancer therapies.
In tandem with the VXA-222 advancement, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047. This robust IP estate underpins VERAXA's commitment to building a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.
The significance of this milestone lies in the potential of VXA-222 to address unmet medical needs in oncology. By advancing this program, VERAXA moves closer to preclinical validation and eventual clinical development. The expansion of the patent portfolio further solidifies the company's position in the competitive landscape of antibody-based therapeutics, ensuring long-term protection for its innovations. For investors, this dual progress—pipeline advancement and IP expansion—signals continued execution on VERAXA's strategic roadmap, potentially enhancing its valuation and competitive advantage.
As VERAXA continues to develop its pipeline, the company remains focused on delivering novel therapies that can improve outcomes for cancer patients. The successful completion of the discovery phase with OmniAb is a testament to the collaborative efforts and the strength of VERAXA's research capabilities. The next steps involve rigorous preclinical validation to assess the efficacy and safety of the final bispecific ADC candidate, with the ultimate goal of advancing it into human clinical trials.
